VolitionRX's CE Marked NuQ(TM) Triage Test has been Commenced in the Capital Region of Denmark
NAMUR, Belgium, March 2, 2017 /PRNewswire/ -- Volition (NYSE MKT: VNRX) announced today that it has begun a two-phase logistical study of the Company's novel Nu.QTMColorectal Cancer Screening Triage blood test. The study is in collaboration with Hvidovre Hospital and The Danish Research Group on Early Detection of Colorectal Cancer; both phases are expected to be completed within 6 months.The first phase of the study starts today in the Capital Region of Denmark and involves three centres and up to 250 subjects. The aim of the study is to evaluate the logistics in collecting and processing blood samples at a local screening centre and subsequently shipping the samples to a central laboratory in Denmark to run the Nu.QTM analysis. This phase is expected to be completed within 2 months.The second phase of the study is due to start after Ethical Approval and will involve five centres and up to 500 subjects. Specifically, this phase will assess the time taken between blood collection, analysis and results. When added to the existing clinical data previously announced, this logistics study aims to complete the information needed to add our test to the national screening program.Morten Rasmussen MD. Ph.D., head of the colorectal screening program in the Capital Region of Denmark, commented "We have been impressed with the preliminary clinical data of the Nu.QTM Colorectal Cancer Screening Triage Test and the potential to reduce unnecessary colonoscopies. Many healthcare systems in Europe, including Denmark, are struggling to meet the increased colonoscopy demand that has come from the implementation of fecal-based colorectal cancer screening programs. Before introducing any such test into the Danish National Screening program, we need to determine the very practical logistics of putting into practice Volition's Nu.QTM Triage Test to ensure a smooth, patient-friendly, and efficient implementation of our screening programme."Volition's CEO Cameron Reynolds added: "This is extremely important news for Volition in the implementation of our commercialisation strategy for our first product. Denmark has one of the most advanced healthcare systems in the world and is viewed by many as strong innovators. We have had a long, mutually beneficial relationship with our collaborators in Denmark and are very pleased that this logistics study will be undertaken to answer key issues to make sure any potential roll out nationally would be smooth. We also envisage this study will assist other countries in assessing the implementation of the Nu.QTM Triage Test within their National Screening Programs."About Nu.QTM Colorectal Cancer Screening Triage TestThere is currently a significant strain on colonoscopy capacity which can lead to longer waiting times in European healthcare systems due to the expansion of colorectal cancer screening programs. Therefore, there is a pressing need to prioritise the colonoscopy referrals for those at high risk. Volition aims to meet this need with its new Nu.QTMColorectal Cancer Screening Triage Test.Having received a CE mark for the Nu.QTM Colorectal Cancer Screening Triage Test in December 2016, Volition plans to launch the test for the European Union screening population.About VolitionVolition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.As cancer screening programs become more and more widespread, our products can help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
RELATED STORIES